Specialist
Former executive at Ada Health GmbH
Agenda
- Ada Health's technological differentiation vs key players including Babylon Healthcare, Doctolib and Doctor Care Anywhere (ASX: DOC)
- Ada Health's position in the US, highlighting its growth potential
- Future applications of Ada Health's technology, including utilisation by big pharma
- Telehealth regulation update, including barriers to entry for new telehealth players
Questions
1.
Could you give an overview of the digital health market? How has coronavirus impacted the uptake of digital health platforms and how do you expect the market to grow YoY?
2.
How would you segment the vast digital health market? You mentioned EHRs [electronic health records] and telemedicine.
3.
How well-positioned is Ada in the access bucket you highlighted? How fragmented is that market?
4.
In which geographies is Ada experiencing the highest market uptake? How has coronavirus impacted this?
5.
Are there any other key competitors who have also launched in India and are experiencing the same uptake as Ada? You mentioned huge growth in countries such as India and Malaysia.
6.
Could you elaborate on the more rigorous performance solutions you referenced and the process around meeting these standards?
7.
Who do you think is best-positioned to meet the standardised benchmark for health AI that will come into play in a couple of years?
8.
Could you outline how the Ada Health platform is set out, how it works and how the app and Ada DX differ?
9.
Where do you think growth will come from? Will it be more from the emerging clinical tool markets?
10.
How is the clinical tool used every day by physicians? Do they use it as a professional diagnostics tool or is it more to monitor the patient’s journey?
11.
Your comments suggest that, from a therapeutic standpoint, rare diseases seem to be the key driver on the clinical side.
12.
How do the costs work for the clinical tool and how is Ada reimbursed for that service? Are patients paying to use it?
13.
How sticky are Ada’s relationships once established?
14.
Could you explain how the app’s technology works? What are its capabilities? What can it do and not do?
15.
You mentioned that the patients can track their symptoms as things change in the long term. Is there any weakness or risk with patient adherence and making sure they’re using the app and tracking every symptom? Integration with the clinician perhaps makes it more of a benefit.
16.
Are patients somewhat limited with measuring their symptoms at home, unlike in a doctor’s office? They don’t necessarily have access to equipment such as blood pressure monitors or stethoscopes. How are telemedicine companies overcoming this potential hurdle?
17.
Are there any key indications besides diabetes and hypertension where you think Ada should partner with players in that therapeutic area?
18.
Ada was named the best-performing symptom app with 70.5% accuracy in a study published in BMJ Open in December 2020. GPs got it right 82% of the time, but Babylon only managed to accurately suggest a condition in around one-third of cases. How should we interpret these results?
19.
The study’s results suggest Babylon is Ada’s closest competition, but it’s still arguably quite behind. How long could it be until competitors such as Babylon catch up with their technology or is Ada on such a large front foot that that’s far away?
20.
How well-placed do you think Ada would be to capture significant market share if a regulatory shift occurred around the system’s approval in the short-to-medium term? You said its accuracy is now held back by regulation not quality.
21.
What are the regulations now and what regulatory shift would there need to be to increase these apps’ use for diagnoses?
22.
What timeline do you expect for the regulation to shift towards Ada being used as a diagnostics tool?
23.
I believe Ada has recently secured USD 90m funding to enhance its health assessment technology. Where should the company focus this investment? What’s the key to the app’s future?
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited
